Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gent – page 37

907 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance
907
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

907 trials in Gent

Open in trial search

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Dermatitis atopic

Not recruiting

Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:GlaxoSmithKline Biologicals

Escherichia infection

Not recruiting

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:ECOO15
  • Sponsor:Janssen Vaccines & Prevention B.V.

Study on Long-Term Safety and Efficacy of Lunsekimig for Adults with Chronic Rhinosinusitis with Nasal Polyps

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Brensocatib
  • Sponsor:Insmed Inc.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

  • Influenza vaccine studies for adults 65+
  • RSV vaccine development
  • Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

  • Nasal decongestant dependency treatment
  • Chronic rhinosinusitis management
  • Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

  • Primary biliary cholangitis treatment
  • Psoriasis therapies
  • Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.